These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 22322877)
21. Reduced risk of recurrent myocardial infarction in homozygous carriers of the chromosome 9p21 rs1333049 C risk allele in the contemporary percutaneous coronary intervention era: a prospective observational study. Hara M; Sakata Y; Nakatani D; Suna S; Usami M; Matsumoto S; Ozaki K; Nishino M; Sato H; Kitamura T; Nanto S; Hamasaki T; Tanaka T; Hori M; Komuro I; BMJ Open; 2014; 4(8):e005438. PubMed ID: 25232560 [TBL] [Abstract][Full Text] [Related]
22. Comparison of Stenting Versus Bypass Surgery According to the Completeness of Revascularization in Severe Coronary Artery Disease: Patient-Level Pooled Analysis of the SYNTAX, PRECOMBAT, and BEST Trials. Ahn JM; Park DW; Lee CW; Chang M; Cavalcante R; Sotomi Y; Onuma Y; Tenekecioglu E; Han M; Lee PH; Kang SJ; Lee SW; Kim YH; Park SW; Serruys PW; Park SJ JACC Cardiovasc Interv; 2017 Jul; 10(14):1415-1424. PubMed ID: 28728654 [TBL] [Abstract][Full Text] [Related]
24. Comparative long-term efficacy and safety of drug-eluting stent versus coronary artery bypass grafting in ostial left main coronary artery disease: analysis of the MAIN-COMPARE registry. Lee SW; Kim SH; Kim SO; Han S; Kim YH; Park DW; Kang SJ; Lee CW; Park SW; Park SJ Catheter Cardiovasc Interv; 2012 Aug; 80(2):206-12. PubMed ID: 22234884 [TBL] [Abstract][Full Text] [Related]
25. Six sequence variants on chromosome 9p21.3 are associated with a positive family history of myocardial infarction: a multicenter registry. Scheffold T; Kullmann S; Huge A; Binner P; Ochs HR; Schöls W; Thale J; Motz W; Hegge FJ; Stellbrink C; Dorsel T; Gülker H; Heuer H; Dinh W; Stoll M; Haltern G; BMC Cardiovasc Disord; 2011 Mar; 11():9. PubMed ID: 21385355 [TBL] [Abstract][Full Text] [Related]
26. Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Patel RS; Schmidt AF; Tragante V; McCubrey RO; Holmes MV; Howe LJ; Direk K; Åkerblom A; Leander K; Virani SS; Kaminski KA; Muehlschlegel JD; Dubé MP; Allayee H; Almgren P; Alver M; Baranova EV; Behlouli H; Boeckx B; Braund PS; Breitling LP; Delgado G; Duarte NE; Dufresne L; Eriksson N; Foco L; Gijsberts CM; Gong Y; Hartiala J; Heydarpour M; Hubacek JA; Kleber M; Kofink D; Kuukasjärvi P; Lee VV; Leiherer A; Lenzini PA; Levin D; Lyytikäinen LP; Martinelli N; Mons U; Nelson CP; Nikus K; Pilbrow AP; Ploski R; Sun YV; Tanck MWT; Tang WHW; Trompet S; van der Laan SW; van Setten J; Vilmundarson RO; Viviani Anselmi C; Vlachopoulou E; Boerwinkle E; Briguori C; Carlquist JF; Carruthers KF; Casu G; Deanfield J; Deloukas P; Dudbridge F; Fitzpatrick N; Gigante B; James S; Lokki ML; Lotufo PA; Marziliano N; Mordi IR; Muhlestein JB; Newton Cheh C; Pitha J; Saely CH; Samman-Tahhan A; Sandesara PB; Teren A; Timmis A; Van de Werf F; Wauters E; Wilde AAM; Ford I; Stott DJ; Algra A; Andreassi MG; Ardissino D; Arsenault BJ; Ballantyne CM; Bergmeijer TO; Bezzina CR; Body SC; Bogaty P; de Borst GJ; Brenner H; Burkhardt R; Carpeggiani C; Condorelli G; Cooper-DeHoff RM; Cresci S; de Faire U; Doughty RN; Drexel H; Engert JC; Fox KAA; Girelli D; Hagström E; Hazen SL; Held C; Hemingway H; Hoefer IE; Hovingh GK; Johnson JA; de Jong PA; Jukema JW; Kaczor MP; Kähönen M; Kettner J; Kiliszek M; Klungel OH; Lagerqvist B; Lambrechts D; Laurikka JO; Lehtimäki T; Lindholm D; Mahmoodi BK; Maitland-van der Zee AH; McPherson R; Melander O; Metspalu A; Pepinski W; Olivieri O; Opolski G; Palmer CN; Pasterkamp G; Pepine CJ; Pereira AC; Pilote L; Quyyumi AA; Richards AM; Sanak M; Scholz M; Siegbahn A; Sinisalo J; Smith JG; Spertus JA; Stewart AFR; Szczeklik W; Szpakowicz A; Ten Berg JM; Thanassoulis G; Thiery J; van der Graaf Y; Visseren FLJ; Waltenberger J; ; Van der Harst P; Tardif JC; Sattar N; Lang CC; Pare G; Brophy JM; Anderson JL; März W; Wallentin L; Cameron VA; Horne BD; Samani NJ; Hingorani AD; Asselbergs FW Circ Genom Precis Med; 2019 Apr; 12(4):e002471. PubMed ID: 30897348 [TBL] [Abstract][Full Text] [Related]
27. Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. Bangalore S; Guo Y; Samadashvili Z; Blecker S; Xu J; Hannan EL J Am Coll Cardiol; 2015 Sep; 66(11):1209-1220. PubMed ID: 26361150 [TBL] [Abstract][Full Text] [Related]
28. The Bypass Angioplasty Revascularization in Type 1 and Type 2 Diabetes Study: 5-year follow-up of revascularization with percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease. Kapur A; Bartolini D; Finlay MC; Qureshi AC; Flather M; Strange JW; Hall RJ J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):26-33. PubMed ID: 19797974 [TBL] [Abstract][Full Text] [Related]
29. Comparison of Five-Year Outcome of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Triple-Vessel Coronary Artery Disease (from the Coronary Revascularization Demonstrating Outcome Study in Kyoto PCI/CABG Registry Cohort-2). Shiomi H; Morimoto T; Furukawa Y; Nakagawa Y; Tazaki J; Sakata R; Okabayashi H; Hanyu M; Shimamoto M; Nishiwaki N; Komiya T; Kimura T; Am J Cardiol; 2015 Jul; 116(1):59-65. PubMed ID: 25956622 [TBL] [Abstract][Full Text] [Related]
30. Impact of chronic kidney disease on patients with unprotected left main coronary artery disease treated with coronary artery bypass grafting or drug-eluting stents. Pan Y; Qiu Q; Chen F; Li X; Yu X; Luo Y; Li Q; He J; Gao Y; Zhang X; Ren X Coron Artery Dis; 2016 Nov; 27(7):535-42. PubMed ID: 27269882 [TBL] [Abstract][Full Text] [Related]
31. Two chromosome 9p21 haplotype blocks distinguish between coronary artery disease and myocardial infarction risk. Fan M; Dandona S; McPherson R; Allayee H; Hazen SL; Wells GA; Roberts R; Stewart AF Circ Cardiovasc Genet; 2013 Aug; 6(4):372-80. PubMed ID: 23729007 [TBL] [Abstract][Full Text] [Related]
32. Polymorphism of 9p21.3 locus is associated with 5-year survival in high-risk patients with myocardial infarction. Szpakowicz A; Pepinski W; Waszkiewicz E; Maciorkowska D; Skawronska M; Niemcunowicz-Janica A; Milewski R; Dobrzycki S; Musial WJ; Kaminski KA PLoS One; 2013; 8(9):e72333. PubMed ID: 24069144 [TBL] [Abstract][Full Text] [Related]
33. Comparison of multivessel percutaneous coronary intervention and coronary artery bypass grafting in patients with severe coronary artery disease presenting with non-ST-segment elevation acute coronary syndromes. Desperak P; Hawranek M; Hrapkowicz T; Zembala MO; Gąsior M Kardiol Pol; 2018; 76(10):1474-1481. PubMed ID: 30251246 [TBL] [Abstract][Full Text] [Related]
34. Comparison of one-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease and acute coronary syndromes (from the CUSTOMIZE Registry). Caggegi A; Capodanno D; Capranzano P; Chisari A; Ministeri M; Mangiameli A; Ronsivalle G; Ricca G; Barrano G; Monaco S; Di Salvo ME; Tamburino C Am J Cardiol; 2011 Aug; 108(3):355-9. PubMed ID: 21545992 [TBL] [Abstract][Full Text] [Related]
35. Clinical application of chromosome 9p21.3 genotyping in patients with coronary artery disease. Nikulina S; Artyukhov I; Shesternya P; Gavrilyuk O; Maksimov V; Voyevoda M; Brusentsov D Exp Ther Med; 2019 Oct; 18(4):3100-3108. PubMed ID: 31572550 [TBL] [Abstract][Full Text] [Related]
36. Impact of diabetes mellitus on the treatment effect of percutaneous or surgical revascularization for patients with unprotected left main coronary artery disease: a subgroup analysis of the MAIN-COMPARE study. Kim WJ; Park DW; Yun SC; Lee JY; Lee SW; Kim YH; Lee CW; Park SW; Park SJ JACC Cardiovasc Interv; 2009 Oct; 2(10):956-63. PubMed ID: 19850255 [TBL] [Abstract][Full Text] [Related]
37. Individual and summed effects of high-risk genetic polymorphisms on recurrent cardiovascular events following ischemic heart disease. Andreassi MG; Adlerstein D; Carpeggiani C; Shehi E; Fantinato S; Ghezzi E; Botto N; Coceani M; L'abbate A Atherosclerosis; 2012 Aug; 223(2):409-15. PubMed ID: 22717531 [TBL] [Abstract][Full Text] [Related]
38. No association of chromosome 9p21.3 variation with clinical and angiographic outcomes after placement of drug-eluting stents. Hoppmann P; Erl A; Türk S; Tiroch K; Mehilli J; Schömig A; Kastrati A; Koch W JACC Cardiovasc Interv; 2009 Nov; 2(11):1149-55. PubMed ID: 19926059 [TBL] [Abstract][Full Text] [Related]
39. Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. Chieffo A; Meliga E; Latib A; Park SJ; Onuma Y; Capranzano P; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Kim YH; Buszman PE; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capodanno D; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A JACC Cardiovasc Interv; 2012 Jul; 5(7):718-27. PubMed ID: 22814776 [TBL] [Abstract][Full Text] [Related]
40. Long-term (10-year) outcomes of stenting or bypass surgery for acute coronary syndromes and stable ischemic heart disease with unprotected left main coronary artery disease. Park S; Ahn JM; Lee K; Kwon O; Park H; Yoon YH; Kang DY; Lee PH; Lee SW; Park SW; Park DW; Park SJ Am Heart J; 2019 Dec; 218():9-19. PubMed ID: 31655415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]